Apellis Pharmaceuticals Inc (NAS:APLS)
$ 43.6 1.04 (2.44%) Market Cap: 5.29 Bil Enterprise Value: 4.95 Bil PE Ratio: 0 PB Ratio: 19.82 GF Score: 38/100

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:45PM GMT
Release Date Price: $68.35 (+14.66%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Alright. Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno, Priyanka Grover, [Gloria Hall].

Our next presenting company is Apellis. And presenting on behalf of the company, we have CEO, Cedric Francois.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you so much, Anupam, and thank you for inviting us again to speak here. It's great to see many familiar faces. Let's dive straight into what is a special year that we have in front of us after 2023, which all of you know had quite a bit of tumultuous events in it. I will be making some forward-looking statements.

And I want to start off with this slide, which reminds us of what we really do at Apellis, where we combine courageous science with compassion. And that has resulted in 2 approved drugs since our time when we went public in 2017,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot